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The role of Ca2+ and protein kinase C (PKC) in the regulation of phosphatidylcholine-hydrolyzing phospholipase D (PLD) was investigated in 
angiotensin II-stimulated mesangial cells. Elevation of cytosolic free Ca *+ by the calcium ionophore, A23187, or the Ca*+-ATPase inhibitor, 
thapsigargin, slightly increased PLD-stimulated phosphatidylethanol formation. However, chelation of cytosolic Ca” with high concentrations of 
quin 2 did not attenuate angiotensin II-induced phosphatidylethanol production, thus suggesting that Ca” is not crucially involved in agonist- 
stimulated PLD activation. Stimulation of PKC by phorbol esters increased PLD activity in mesangial cells. Down-regulation of PKC-a and -6 
isoenzymes by 8 h phorbol ester treatment still resulted in full PLD activation. In contrast, a 24 h treatment of mesangial cells with phorbol ester, 
a regimen that also causes depletion of PKC-.s, abolished angiotensin II-evoked phosphatidylethanol formation. In addition, the selective PKC 
inhibitor, calphostin C, attenuated hormone-induced PLD activity. In summary, these data suggest that angiotensin II stimulation of phospholipase 
D appears to involve the PKC-& isoenzyme, activated by DAG derived from phosphoinositide hydrolysis. 
Angiotensin II; Phospholipase D; Protein kinase C; Isoenzyme; Mesangial cell 
1. INTRODUCTION 
Mesangial cells are an important determinant in the 
regulation of the glomerular titration rate. Morpholog- 
ically, mesangial cells resemble vascular smooth muscle 
cells, able to contract upon stimulation by vasoactive 
hormones like angiotensin II [l]. Angiotensin II binds 
to specific AT, receptors on the surface of mesangial 
cells and triggers the rapid generation of inositol 1,4,5- 
trisphosphate and 1,2-diacylglycerol (DAG), which are 
concomitantly formed by the hydrolysis of phosphati- 
dylinositol 4,5bisphosphate [ 1,2]. Inositol 1,4,5-t& 
phosphate mobilizes Ca*’ from intracellular storage 
sites and DAG activates protein kinase C (PKC). These 
biochemical signals are thought to interact to cause a 
wide variety of cellular responses [3,4]. 
whether phospholipase D activation is dependent upon 
prior phosphoinositide hydrolysis, Ca*+ mobilization 
and protein kinase C activation. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
[‘H]Myristic acid was purchased from Amersham International, 
UK; cell culture media and nutrients were from Gibco BRL, Basel, 
Switzerland; calphostin C, K252a, CGP 41251 and CGP 42700 were 
from Ciba-Geigy Ltd., Basel, Switzerland; angiotensin II, phorbol 
12-myristate 13-acetate (PMA), 4o-phorbol 12,13_didecanoate 
(PDD), and phorboll2,13dibutyrate (PDBu) were from Calbiochem, 
Lucerne, Switzerland. TLC plates and all other chemicals used were 
either from Merck, Darmstadt, Germany, or from Fluka, Buchs, Swit- 
zerland. 
2.2. Cell culture 
Another important signalling pathway appears to act 
exclusively on phosphatidylcholine in response to a 
wide variety of agonists and thus generates phospha- 
tidic acid and DAG from lipid sources other than 
phosphoinositides [5,6]. In mesangial cells, angiotensin 
II [7], platelet-derived growth factor [8], endothelin [9], 
vasopressin [lo] and extracellular nucleotides [1 l] have 
been reported to stimulate phosphatidylcholine hydrol- 
ysis by phospholipase D activity. 
In the present study we addressed the question 
*Corresponding author. Fax: (41) (61) 267 2208. 
Abbreviations: PKC, protein kinase C, DAG, 1,2-diacylglycerol; PLD, 
phospholipase D; PMA, phorbol 1Zmyristate 13-acetate; PDD, 4a- 
phorbol 12,13-didecanoate; PDBu, phorbol 12,13dibutyrate. 
Rat glomerular mesangial cells were cultured as described previ- 
ously [12]. In a second step, single cells were cloned by limited dilution 
using 96-microwell plates. Clones with apparent mesangial cell mor- 
phology were used for further processing. The cells exhibited the 
typical stellate morphology. Moreover, there was positive staining for 
the intermediate filaments, desmin and vimentin, which are considered 
to be specific for myogenic cells [13], positive staining for Thy 1.1 
antigen, negative staining for factor VIII-related antigen and cytoke- 
ratin-excluded endothelial and epithelial contaminations, respectively. 
The generation of inositol trisphosphate upon activation of the angio- 
tensin II AT, receptor was used as a functional criterion for charac- 
terizing the cloned cell line [2]. The cells were grown in RPM1 1640 
supplemented with 10% fetal calf serum, penicillin (100 U/ml), strepto- 
mycin (100 &ml) and bovine insulin at 0.66 U/ml (Sigma). 
2.3. Determination of ['H]phosphatidylethanoi pr duetion 
Angiotensin II-stimulated phosphatidylcholine hydrolysis was 
measured in cells pre-labelled for 24 h with [‘Hjmyristic acid (2.0 
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@i/ml; specific activity 54 Ci/mmol). Pre-labelled confluent cells were 
washed several times with medium to remove unincorporated label. 
The cells were incubated for a further 1 h. Ethanol was added to cell 
monolayers 5 min prior to the addition of angiotensin II. Incubations 
were terminated by collecting the medium and adding ice-cold metha- 
nol to the cells. After harvesting the cells from the dishes with a rubber 
policeman, lipids were extracted according to Bligh and Dyer [13]. 
Radioactivity in aliquots of medium, aqueous phase and chloroform 
phase was determined. Lipid extracts were separated by thin-layer 
chromatography, developed with the top phase of ethyl acetate/2,2,4- 
trimethyl pentandacetic acid/water (13:2:3:10, by vol.) for separation 
of phosphatidylethanol. 
2.4. Statistical analysis 
Statistical analysis was performed by one-way analysis of variance 
(ANOVA). For multiple comparisons with the same control group, 
the limit of significance was divided by the number of comparisons, 
according to Bonferroni. 
3. RESULTS AND DISCUSSION 
ested to investigate what role, if any, the increased intra- 
cellular Ca2’ and PKC play in angiotensin II-stimulated 
phospholipase D-mediated phosphatidylcholine hy- 
drolysis. The requirement of Ca2’ for phospholipase D 
activity was examined using the Ca2+ ionophore, 
A 23187, the Ca” ATPase inhibitor, thapsigargin, and 
by chelation of intracellular Ca” with high concentra- 
tions of quin 2. As shown in Fig. 1, A23187 (1 PM) and 
thapsigargin (200 nM) slightly increased phosphatidyl- 
ethanol formation. However, chelation of cytosolic 
Ca2’ with high doses of the Cat’ buffer quin 2 did not 
attenuate angiotensin II-stimulated phosphatidyletha- 
no1 formation (Fig. I), thus suggesting that an increase 
in cytosolic free Ca*+ is not essential for phospholipase 
D activation by nucleotides in mesangial cells. In this 
connection it is noteworthy that endothelin-stimulated 
phospholipase D was found to be Ca”-independent in 
mesangial cells [9]. 
We have previously shown that angiotensin II trig- The possible involvement of PKC in hormone stimu- 
gers a delayed but sustained activation of phosphati- lation of phospholipase D activity was examined using 
dylcholine-degrading PLD activity in mesangial cells. phorbol esters, PKC down-regulation experiments, as 
The potent inhibitory action of Dup 753 and the ineffec- well as a specific inhibitor of PKC. As shown in Fig. 2 
tiveness of CGP 42112A on angiotensin II-stimulated the PKC activators PMA and PDBu caused a marked 
choline and phosphatidylethanol formation, as well as increase in phosphatidylethanol production. In con- 
the rank order of potency of angiotensin II, angio- trast, the biologically inactive phorbol ester, PDD, did 
tensin( l-7) and angiotensin( l-6) clearly demonstrated not activate phospholipase D (Fig. 2). Furthermore, 
that this action is due to angiotensin II AT, receptor PKC down-regulation by prolonged PMA treatment 
activation [7]. The mechanism by which hormones such (24 h) blocked angiotensin-II stimulated phosphatidyl- 
as angiotensin II activate PLD is still under debate. ethanol synthesis (Fig. 3). Stimulation of PLD is almost 
There is substantial evidence that PLD stimulation is a universal cellular response to phorbol ester treatment 
secondary to phosphoinositide hydrolysis and is medi- [3,4]. However, the mechanism by which phorbol esters 
ated to varying degrees by Ca2+ and PKC [3,4]. How- activate PLD is not known. It is well established that 
ever, other investigations have implicated G-proteins as PMA and PDBu bind to and activate PKC, but other 
direct activators of PLD [3,4]. In an attempt o address cellular substrates have also been described. In fact, a 
this issue in mesangial cells we were, therefore, inter- recent study provided evidence that PKC may activate 
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Fig. 1. Effects of Ca*’ on phosphatidylethanol (PEt) formation in mesangial cells. Confluent cells were labelled for 24 h with [‘Hlmyristic acid and 
pretreated for 60 min with 1OOpM quin UAM where indicated. Cultures were then stimulated with angiotensin II (AH, 100 nM), the Ca*+ ionophore, 
A23187 (1 PM), or the Ca’+-ATPase inhibitor, thapsigargin (Tg, 200 nM), for 10 min in the presence of 1% ethanol. Lipid extraction and separation 
was performed as described in section 2. Results are means f SD. of four experiments. Significant differences from control: ***P <: 0.001; ANOVA. 
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Fig. 2. Phorbol ester-stimulation f phosphatidylethanol (PEt) formation in mesangial cells. Confluent cells were labelled for 24 h with [‘Hlmyristic 
acid and then stimulated with PMA (100 nM), PDBu (100 nM) or PDD (100 nM) for 10 min in the presence of 1% ethanol. Lipid extraction and 
separation was performed as described in section 2. Results are means k S.D. of four experiments. Significant differences from control: 
***P c 0.001: ANOVA. 
PLD by a phosphorylation-independent event [14]. to PMA, these isoenzymes displayed distinctly different 
Moreover, molecular cloning has revealed that PKC down-regulation kinetics. An 8 h treatment with PMA 
exists as a family of at least ten molecular species, all was sufficient to completely deplete mesangial cells of 
having closely related structures but differing in tissue PKC-ol and -6 isotypes, and a 24 h incubation with 
and cellular distribution and in their individual enzy- PMA was necessary to down-regulate PKGE. In con- 
mological characteristics [3]. By immunoblot analysis trast, PMA treatment for 24 h did not include any deple- 
we have shown previously that mesangial cells express tion of PKC-< [15-l 81. By comparing the down-regula- 
4 PKC isoenzymes, PKC-a, -S, -E and -c. No PKC-/I, tion kinetics of the mesa&al cell PKC isoenzymes with 
-y and -?I isoforms were detected [15-181. On exposure the timeecourse of removal of the specific cellular func- 
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Fig. 3. Effects of PKC down-regulation on angiotensin II-stimulated phosphatidylethanol (PEt) formation in mesangial cells. Confluent cells were 
labelled for 24 h with [3Hjmyristic acid and either non-pretreated (control) or pretreated for 8 h or 24 h with PMA (500 nM) as indicated. Cultures 
were then washed and stimulated with angiotensin II (AIL 100 PM) or vehicle (0) for 10 min in the presence of 1% ethanol. Lipid extraction and 
separation was performed as described in section 2. Results are means f SD. of four experiments. Signiticant differences from corresponding 
control (without stimulation): ***P < 0.001; ANOVA. Significant differences from corresponding control angiotensin II stimulation (without PMA 
pretreatment): +++P < 0.001; ANOVA. 
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Fig. 4. Effects of PKC inhibitors on angiotensin II-stimulated phosphatidylethanol (PEt) formation in mesangial cells. Confluent cells were labelled 
for 24 h with [3H]myristic acid and pretreated for 30 min with calphostin C (1 PM), K-252a (250 nM), CGP 41251 (250 nM), CGP 42700 (250 
nM) or vehicle (Control). Cultures were then stimulated with angiotensin II (AII, 100 nM) or vehicle (0) for 10 min in the presence of 1% ethanol. 
Lipid extraction and separation was performed as described in section 2. Results are means f S.D. of four experiments. Significant differences from 
corresponding control: ***P C 0.001; **P c 0.01; ANOVA. Significant differences from corresponding angiotensin II stimulation in the absence 
of inhibitor: ++P c 0.01; +P < 0.05, ANOVA. 
tions, we have suggested that PKC-a may negatively 
regulate phosphoinositide turnover in response to 
angiotensin II [ 15-l 7,191, whereas PKC-E is a candidate 
for regulation of phospholipase AZ and prostaglandin 
synthesis in mesangial cells [15]. Using this type of 
down-regulation regimen to differentially deplete PKC 
isoenzymes from mesangial cells we wanted to address 
the question which of the four isoforms present in the 
cells is involved in regulating PLD activity. An 8 h 
treatment with PMA that causes depletion of 01- and 
&isoenzymes of PKC in mesa&al cells [15,16] was not 
sufficient to eliminate angiotensin II-induced phospho- 
lipase D activation (Fig. 3). It was necessary to pre- 
incubate the cells for 24 h with PMA, a regimen that 
also causes depletion of PKC-& [ 151, to fully prevent the 
responses to angiotensin II (Fig. 3). Moreover, the se- 
lective PKC inhibitor, calphostin C (1 PM), which inter- 
acts with the regulatory domain of the enzyme [20], 
attenuated angiotensin II-stimulated phosphatidyletha- 
no1 formation (Fig. 4). In summary, these data suggest 
that PKC-& may not only activate phospholipase A2 in 
mesangial cells, but also phosphatidylcholine-specific 
PLD. 
In this connection it is worth noting that inhibitors 
of PKC which display a selectivity for the Ca*‘-depend- 
ent group A isoenzymes, as compared to the Ca*+-inde- 
pendent group B isotypes, such as staurosporine, K- 
252a or the specific PKC inhibitor, CGP 41251 ([21-231, 
Mate, B.M., Meyer, T., Stabel, S., Jaken, S., Fabbro, 
D. and Hynes, N.E., manuscript submitted), did not 
270 
inhibit angiotensin II-induced phospholipase D activa- 
tion (Fig. 4). In contrast, K-252a and CGP41251 even 
potentiated angiotensin II-induced PLD activity (Fig. 
4). A possible explanation for this observation may be 
the potent inhibition of the Ca*+-dependent PKC-a by 
these inhibitors. As PKC-a mediates the feedback inhi- 
bition of hormone-stimulated phosphoinositide turno- 
ver in mesangial cells [15,16], pretreatment of cells with 
the inhibitors results in an augmentation of inositol 
trisphosphate and DAG formation in response to 
angiotensin II [19]. The increased generation of DAG 
may cause a pronounced activation of PKC isotypes, 
including PKC-E, and thereby potentiate PLD activity. 
As a control, we have also included CGP 42700, a stau- 
rosporine derivative that is devoid of any PKC inhib- 
itory activity [23]. Fig. 4 shows that CGP 42700 did not 
alter basal or hormone-induced formation of phospha- 
tidylethanol. Failure to achieve inhibition of PLD with 
PKC inhibitors has led to the suggestion that phorbol 
ester may act, in part, through a PKC-independent 
mechanism [5,6]. Our observation could provide an al- 
ternative explanation for some of these reports. How- 
ever, one should be aware that there may be a cell 
type-specific link between certain PKC isoenzymes and 
PLD activation. Over-expression of PKCB, in fibro- 
blasts has been reported to enhance PLD activity after 
PMA or endothelin-1 stimulation [24,25]. Furthermore, 
over-expression of PKC-a in Swiss 3T3 fibroblasts up- 
regulates PLD, leading to a constitutive higher level of 
enzyme activity [26]. On the other hand, DAG derived 
Volume 33 1, number 3 FEBSLETTERS October 1993 
from PLD-mediated phosphatidylcholine hydrolysis 
has been shown to selectively activate PKC-/? in inter- 
feron-a-activated leucocytes [27] and PKC-c in acti- 
vated Xenopus oocytes [28]. Thus, PKC-mediated acti- 
vation of PLD, and the subsequent generation of DAG, 
may provide a positive-feedback loop to sustain PKC 
activation in cells. Whether phosphatidylcholine hy- 
drolysis, prolonged formation of DAG and sustained 
activation of PKC are a common response to mitogenic 
signals that crucially function in mitogenic signal 
transduction, as recently suggested by Cook and 
Wakelam [29], remains to be elucidated. 
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